Form 4: Nutex Health Director's RSU Grant Filed Late

Nutex Health Inc. Director Scott J. Saunders received a grant of 603 Restricted Stock Units, with the filing significantly delayed.

Summary

• Scott J. Saunders, a Director of Nutex Health Inc. (NUTX), was granted 603 Restricted Stock Units (RSUs) on July 14, 2025.
• Each RSU represents a contingent right to receive one share of the issuer's common stock, $0.001 par value, upon vesting.
• The RSUs are scheduled to vest 100% on July 14, 2026.
• If the reporting person leaves service with the company without cause during the vesting period, the RSUs will vest on a pro-rata basis for the actual time in service.
• The Form 4 reporting this transaction was signed on February 9, 2026, indicating a significant delay in filing for a transaction that occurred on July 14, 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing negatively due to the significant delay in reporting a director's equity grant, which raises concerns about corporate governance and compliance with SEC regulations, despite the routine nature of the grant itself.

Positives

• The grant of Restricted Stock Units to a director aligns management's interests with shareholders for long-term performance.

Negatives

• The Form 4 filing for a transaction on July 14, 2025, was signed on February 9, 2026, representing a significant delay in reporting, which raises concerns about compliance with SEC regulations.

Risks

• RSUs vest pro-rata if the reporting person leaves service with the company without cause during the vesting period, potentially reducing the full benefit.
• The significant delay in filing this Form 4 indicates a potential compliance risk regarding timely disclosure of insider transactions.

Future Outlook

The 603 Restricted Stock Units granted to Director Scott J. Saunders are scheduled to vest 100% on July 14, 2026, contingent on continued service or pro-rata vesting under specific conditions.

Industry Context

StockSavvy.ai notes that equity grants like RSUs are a common form of executive and director compensation across various industries, particularly in healthcare, to incentivize long-term performance and align interests with shareholders. However, timely filing of such transactions is a critical aspect of corporate governance and regulatory compliance.

Comparison to Industry Standards

• The grant of 603 RSUs to a director is a standard practice for aligning interests, comparable to similar grants seen at small to mid-cap healthcare companies.
• The one-year cliff vesting schedule (vesting 100% on a specific future date) is a common structure, though multi-year graded vesting is also prevalent in the industry.
• The significant delay in filing this Form 4 (over six months) falls short of industry best practices and SEC requirements, which mandate filing within two business days of the transaction.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with the company's long-term performance. However, the late filing could raise concerns about transparency and corporate governance.
• Regulatory Authorities: The delayed filing may attract scrutiny from the SEC regarding compliance with Section 16(a) reporting requirements.

Next Steps

• The 603 RSUs are scheduled to vest on July 14, 2026.

Key Dates

Recommendation

While the RSU grant itself is a routine compensation event, the significant delay in filing this Form 4 (transaction on July 14, 2025, filed February 9, 2026) raises concerns about corporate governance and compliance. This late filing is a negative signal, but without further context on the reason for the delay or its broader implications, a 'hold' recommendation is appropriate, suggesting investors monitor for further information regarding compliance practices.

Keywords

Nutex Health, NUTX, Restricted Stock Units, RSU, Director Compensation, Insider Transaction, Equity Grant, Form 4, Late Filing, Compliance Risk